Johnson & Johnson 2003 Annual Report (10-K) Summary
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 28, 2003. Johnson & Johnson is a global healthcare company employing approximately 110,600 people and operating through over 200 subsidiaries in virtually all countries. The company is organized into three primary business segments: Consumer (baby care, skin care, OTC pharmaceuticals), Pharmaceutical (prescription drugs), and Medical Devices and Diagnostics. The company operates 154 manufacturing facilities worldwide.
Key Financial Metrics
Note: Specific consolidated revenue, net income, cash flow, and debt figures are incorporated by reference to the Annual Report to Shareholders (Exhibit 13) and are not explicitly detailed in the provided text.
- Research and Development (R&D): $4,684 million for fiscal year 2003 (compared to $3,957 million in 2002 and $3,591 million in 2001).
- Market Capitalization: Approximately $153 billion (aggregate market value of common stock held by non-affiliates as of the end of the second fiscal quarter).
- Shares Outstanding: 2,967,840,022 shares as of February 24, 2004.
- Valuation Reserves (2003): Total reserves deducted from accounts receivable were $561 million, including $192 million for doubtful accounts and $314 million for customer rebates.
Material Changes and Operational Highlights
- R&D Investment: R&D costs increased significantly to $4,684 million in 2003, reflecting continued investment in new product development.
- Patent Expirations: The filing notes that EPREX (PROCRIT), DURAGESIC, and certain contraceptive products have or will lose basic patent protection within two years, exposing approximately 6% of annual worldwide sales to generic competition.
- Key Product Concentration: Sales of PROCRIT and RISPERDAL each accounted for over 5% of total revenues in 2003.
- Executive Changes: James T. Lenehan announced his retirement as President and Vice Chairman effective February 1, 2004, and June 30, 2004, respectively. Roger S. Fine is scheduled to retire as Vice President, General Counsel, on April 1, 2004.
Outlook, Risks, and Subsequent Events
Subsequent Event: On February 24, 2004, the Cordis operating company entered a strategic alliance with Guidant Corporation to co-promote the CYPHER Sirolimus-eluting Coronary Stent in the U.S. This agreement also settled all outstanding patent disputes between the two companies.
Risks and Contingencies:
- Regulatory Environment: Increasing stringency in government regulation (FDA, international) regarding product safety, efficacy, and pricing. Uncertainty remains regarding the impact of the Medicare Prescription Drug, Improvement and Modernization Act enacted in late 2003.
- Legal Proceedings: The company is involved in various proceedings under the Comprehensive Environmental Response, Compensation, and Liability Act (Superfund). Management does not believe these will have a material adverse effect.
- Competition: Strong competition exists in all product lines, particularly in research and development, which can lead to product obsolescence.
Investor Verification Checklist
- Verify the specific consolidated revenue, net income, and cash flow figures in the Annual Report to Shareholders (Exhibit 13), as they are not explicitly listed in the 10-K text provided.
- Review the Legal Proceedings (Note 18) in the Annual Report for details on environmental liabilities and other litigation.
- Assess the impact of the strategic alliance with Guidant on future revenue streams for the Medical Devices segment.
- Monitor the timeline for patent expirations on PROCRIT, DURAGESIC, and contraceptives and the company's strategy to mitigate generic competition.
- Confirm the status of the Medicare Prescription Drug Act implementation and its potential effect on pharmaceutical pricing and margins.